HSHaruhiko Suzuki

Haruhiko Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haruhiko Suzuki has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuyuki Akane

    Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan

    2 shared publications
  • Seiji Kojima

    Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan

    2 shared publications
  • Yusuke Okuno

    Department of Virology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    2 shared publications
  • Akemi Hayakawa

    Org Promoting Life Sci & Culture, Nagoya, Japan

    1 shared publication
  • Akina Oishi

    Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    1 shared publication
  • Atsushi Enomoto

    Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan

    1 shared publication

Latest Publications

  • Open Access

    Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease

    by Jingxi Mu, Keiko Maeda, Tadashi Iida, Shinji Mii, Nobutoshi Esaki, Yukihiro Shiraki, Yasuyuki Mizutani, Masanao Nakamura, Takeshi Yamamura, Tsunaki Sawada, et al.

    Dysfunctional intestinal fibrosis is an irreversible complication of Crohn’s disease (CD), The complex heterogeneity of intestinal mesenchymal cells makes it difficult to understand the pathogenesis of intestinal fibrosis. Previously, we identified Meflin as a marker of fibroblast subsets. This study aimed to explore the role of Meflin-positive fibroblasts in intestinal fibrogenesis and investigate the potential of pharmacological control of Meflin expression as a treatment for patients with CD. Our results indicated that Meflin expression was upregulated in fibroblasts at the early stage of fibrosis but was downregulated in established fibrosis in both patients with CD and two different mouse models, which are the chronic dextran sodium sulfate (DSS) model and an interleukin-10-deficient model that spontaneously develops intestinal inflammation. Meflin-deficient mice exacerbated intestinal fibrosis with dysregulated expression of non-canonical Wnt ligand WNT5A and its receptor ROR2. Pharmacologically induced Meflin expression through the administration of a synthetic retinoid reversed intestinal fibrosis in the DSS model and suppressed pro-fibrotic protein secretion in fibroblasts isolated from patients with CD. Our findings indicate that Meflin-positive fibroblasts represent a functional subpopulation that suppresses intestinal fibrosis. Augmentation of Meflin expression shows antifibrotic effects and holds promise as a therapeutic approach for intestinal fibrosis in patients with CD.


  • Hydroxyapatite-coated titanium oxide ameliorates dextran sulphate sodium-induced colitis by attenuating both innate and acquired immune reaction

    by Akemi Hayakawa, Hideki Kanda, Yuzuru Kamei, Haruhiko Suzuki

    Introduction Titanium oxide (TiO2) is a widely used oxidizer for environmental management. The power of TiO2 has been demonstrated by its photocatalytic activity. Hydroxyapatite (HA)-coated TiO2 (HA-TiO2) was used to test the in vivo effect on dextran sulphate sodium (DSS)-induced colitis in...

  • CD8+CD122+CD49dlowregulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity

    by Kazuyuki Akane, Seiji Kojima, Tak W. Mak, Hiroshi Shiku, Haruhiko Suzuki

    Significance: Our study demonstrated that CD8+CD122+CD49dlowregulatory T cells induced apoptosis in target T cells depending on death receptor Fas (CD95)–FasL (CD178) interaction. This in vitro phenomenon reflected the regulatory activity of these cells in vivo, which was also reproducible in the in vivo experimental system of adoptive T-cell transfer. By using natural mutant mice of Fas or FasL and the gene-targeted mice of IL-10, we confirmed that the regulatory activity of CD8+CD122+CD49dlowcells was mediated by Fas–FasL but not by IL-10. In addition, the necessity of MHC class I molecules on the target T cells was also confirmed by analysis using CD8+T cells that lack β2-microglobulin and consequently class I MHC.


  • CD8+ CD122+ regulatory T cells contain clonally expanded cells with identical CDR3 sequences of the T‐cell receptor β‐chain

    by Yusuke Okuno, Ayako Murakoshi, Masashi Negita, Kazuyuki Akane, Seiji Kojima, Haruhiko Suzuki

    We identified CD8+CD122+ regulatory T cells (CD8+CD122+ Treg cells) and reported their importance in maintaining immune homeostasis. The absence of CD8+CD122+ Treg cells has been shown to lead to severe systemic autoimmunity in several mouse models, including inflammatory bowel diseases and experimental autoimmune encephalomyelitis. The T-cell receptors (TCRs) expressed on CD8+CD122+ Treg cells recognize the target cells to be regulated. To aid in the identification of the target antigen(s) recognized by TCRs of CD8+CD122+ Treg cells, we compared the TCR diversity of CD8+CD122+ T cells with that of conventional, naive T cells in mice. We analysed the use of TCR-V in the interleukin 10-producing population of CD8+CD122+ T cells marked by high levels of CD49d expression, and found the significantly increased use of V13 in these cells. Immunoscope analysis of the complementarity-determining region 3 (CDR3) of the TCR -chain revealed remarkable skewing in a pair of V regions, suggesting the existence of clonally expanded cells in CD8+CD122+ T cells. Clonal expansion in V13+ cells was confirmed by determining the DNA sequences of the CDR3s. The characteristic TCR found in this study is an important building block for further studies to identify the target antigen recognized by CD8+CD122+ Treg cells.


  • Are CD8+CD122+ cells regulatory T cells or memory T cells?

    by Haruhiko Suzuki, Zhe Shi, Yusuke Okuno, Ken-Ichi Isobe